Opportunity ID: 358795
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | HT942525RCRPRCDA |
Funding Opportunity Title: | DoD Rare Cancers, Resource and Community Development Award |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Science and Technology and other Research and Development |
Category Explanation: | – |
Expected Number of Awards: | 5 |
Assistance Listings: | 12.420 — Military Medical Research and Development |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | May 01, 2025 |
Last Updated Date: | May 01, 2025 |
Original Closing Date for Applications: | Oct 06, 2025 |
Current Closing Date for Applications: | Oct 06, 2025 |
Archive Date: | – |
Estimated Total Program Funding: | $5,600,000 |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
Additional Information on Eligibility: |
Additional Information
Agency Name: | Dept. of the Army — USAMRAA |
Description: |
Summary: The fiscal year 2025 (FY25) Rare Cancers Research Program (RCRP) Resource and Community Development Award (RCDA) supports the development of research resources and clinical or preclinical data sets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Major gaps to be filled by this funding opportunity include: · Lack of research and clinical resources, including patient tissues, cell, and tumor models. · Lack of communication and dissemination strategies within scientific and patient communities for sharing rare cancers research and clinical findings. · Lack of infrastructure for sharing data and other resources. · Lack of therapeutics and mechanistic research to inform treatment development. Distinctive Features: · Engagement and partnerships with Patient Advocates must be integrated into the project from development of the research question through the execution of the study. · Community building and enhancement are key components. · Dissemination and sustainability of the platform for scientific and/or clinical, and patient community must be described. · Preliminary data not required but may be included to address feasibility. Funding Details: (New for FY25) Funding limits are now listed as total cost limits, which is the combination of both direct and indirect costs. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
Packages
Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
12.420 | PKG00290674 | May 01, 2025 | Oct 06, 2025 | View |